Award
National Cancer Institute 5R37CA278744-03
Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer
Recipient
Stanford University
Award Amount
$485,341.00
Ceiling
$485,341.00
Awarded
February 26, 2026
Identifier
5R37CA278744-03
Development of MUC1-targeted theranostic peptides for imaging and radionuclide therapy of triple-negative breast cancer, focusing on peptide design, radiolabeling, and preclinical testing.
Description
This project aims to develop theranostic peptides targeting MUC1, a protein overexpressed in 94% of triple-negative breast cancer cases, for imaging and radionuclide therapy. The approach involves designing peptides with high affinity and stability, radiolabeling with gallium-68 and lutetium-177, and testing in mouse models to create a clinically translatable treatment to reduce mortality and improve management of TNBC.